Skip to content

Posts tagged ‘neurodegeneration’

Dementia: why don’t we have any treatments yet?

Alois Alzheimer first described his eponymous disease a century ago, but there are still no effective treatments. For World Alzheimer’s Day, Professor Bart de Strooper, Director of the UK Dementia Research Institute, asks why that is, and tells us how that might all be about to change.

Bart de Strooper UK Dementia Research Institute

Professor Bart de Strooper

In the early 1900s, a German neurologist called Alois Alzheimer became obsessed with studying an Asylum patient in her 50s, who had started to show unusual behavioural changes, including short-term memory loss. After her death he examined her brain and discovered structures known as amyloid plaques and neurofibrillary tangles – the hallmarks of what became known as Alzheimer’s disease.  So why, when we’ve known about the disease for so long, are there still no treatments? Read more

Why MRC-industry asset sharing is a win-win for me

Just how useful is it to get access to a pharmaceutical company compound? Back in 2012 Dr Richard Mead of the University of Sheffield was one of 15 academic project leaders funded by the MRC to research an alternative use for a compound no longer being developed by AstraZeneca. As we launch the next round of the MRC-Industry Asset Sharing Initiative he tells us how the collaboration has brought together the best of both worlds.

Copyright: Richard Mead

Copyright: Richard Mead

I’m no stranger to the pharmaceutical industry. I spent three years in drug development at Celltech in the early 2000s. But even with my experience, it’s still amazing to be reminded of the resources that pharmaceutical companies have at their fingertips. It sounds obvious, but their access to unique compounds, and their ability to make them, is impressive. Read more